Hemlibra Hits The Heights In HAVEN Hemophilia Trials
Full results from the HAVEN 3 and 4 trials suggest that Roche’s hemophilia drug Hemlibra will indeed take a dominant market position in patients with or without factor VIII inhibitors although that make take some time as current therapy is already very effective and is supported by decades of safety experience.
You may also be interested in...
The company believes there is room in the market for its more standard-acting hemophilia A products Kogenate and Kovaltry, as well as a long half-life product like Jivi.
Development guidance from CBER recommends comparing investigational gene therapy products to existing prophylaxis treatment.
Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key new products reach the global market and others begin to face generic competition. In this second and final part of an exclusive interview with Scrip, he talks about major mid-term growth prospects, recent pricing reforms in Japan, and how Chugai is tapping into novel disruptive technologies.